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The presence of autoantibodies in multiple sclerosis
(MuS) is well known, but their target antigens have not
been clearly identified. In the present study, IgG autore-
activity to neural antigens of normal human white matter
separated by bidimensional electrophoresis was assessed
in serum and cerebrospinal fluid of 18 MuS and 20 control
patients. Broad IgG autoreactivity was detected by two-
dimensional immunoblotting in all cases to neural antigens,
most of which were identified by mass spectrometry. The
comparative analysis of MuS and non-MuS reactive spots
showed that a restricted number of neural protein isoforms
were specifically recognized by MuS IgG. Almost all MuS
patients had cerebrospinal fluid IgG directed to isoforms of
one of the oligodendroglial molecules, transketolase, 2,3-
cyclic-nucleotide 3-phosphodiesterase type I, collapsin re-
sponse mediator protein 2, and tubulin 4. Interestingly
50% of MuS IgG recognized transketolase, which was
mostly localized on oligodendrocytes in human white mat-
ter from normal and MuS samples. IgG autoreactivity to
cytoskeletal proteins (radixin, sirtuin 2, and actin-interact-
ing protein 1) was prevalent in secondary progressive MuS
patients. Among the proteins recognized by serum IgG,
almost all MuS patients specifically recognized a restricted
number of neuronal/cytoskeletal proteins, whereas 2,3-
cyclic-nucleotide 3-phosphodiesterase type I was the oli-
godendroglial antigen most frequently recognized (44%) by
MuS seric IgG. Our immunomics approach shed new light
on the autoimmune repertoire present in MuS patients re-
vealing novel oligodendroglial and/or neuronal putative au-
toantigens with potential important pathogenic and diag-
nostic implications. Molecular & Cellular Proteomics 7:
2337–2349, 2008.
Multiple sclerosis (MuS)1 is an inflammatory disease of the
central nervous system (CNS) in which the autoimmune re-
sponse is directed to myelin and myelin-producing cells, the
oligodendrocytes, and eventually leads to demyelination and
oligodendrocyte loss (1). The autoimmune reaction has been
shown to involve the activation of both T and B lymphocytes
(2). The role of autoantibodies in MuS pathogenesis was
suspected several years ago and has been confirmed recently
by studying the autoreactivity of MuS sera to oligodendro-
cytes (3–5). In addition, accurate neuropathological studies
have provided evidence that antibody-mediated autoimmune
mechanisms contributed to lesion formation in a subset of
MuS patients (6). Although MuS has long been regarded as a
pure demyelinating disorder of the CNS, axonal degeneration
was reported in early descriptions of MuS plaques and re-
gained attention in recent years, now being recognized as an
important pathological feature even in early MuS lesions and
correlating with disease progression (7, 8). The mechanisms
leading to axonal damage in MuS are largely unknown. Axonal
damage is probably independent of demyelination (9), and a
very recent study suggested that its pathogenesis is also
autoantibody-mediated with neurofascin as a major autoanti-
gen (10).
Despite extensive efforts, the molecular targets of the au-
toimmune response leading to demyelination in MuS have yet
to be clearly defined. Among the myelin proteins investigated
as potential targets for T or B cells, most studies have been
focused on myelin basic protein (MBP), proteolipid lipoprotein
(PLP), myelin oligodendrocyte glycoprotein (MOG), 2,3-cy-
clic-nucleotide 3-phosphodiesterase type I (CNPase I), and
synthetic peptides (11–14), whereas anti-cytoskeleton IgG
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has been associated with disease progression (10, 15, 16). To
date, no MuS-specific biological markers have been identified
(16). This may be due to the use of purified antigens and/or
relevant peptides from preselected targets for the detection of
autoantibodies in MuS patients. We have overcome such a
restrictive approach by using a large panel of antigens derived
from target tissue extracts. In the present study, we com-
pared by bidimensional (2D) PAGE and immunoblotting the
IgG repertoires from serum and cerebrospinal fluid (CSF) of
control and MuS patients against antigens derived from
CNS normal white matter. The reactive spots were then
identified by MS and/or immunoblotting. This immunomics
approach enabled the identification of a restricted number
of neural protein isoforms specifically recognized by MuS
sera and CSF that were mostly localized on oligodendro-
cytes and/or cytoskeleton. Besides the confirmation of anti-
CNPase I IgG in MuS sera (13), the study of CSF IgG
autoreactivity provided the most interesting information. Al-
most all MuS CSF displayed autoreactivity to oligodendro-
glial antigens, the most frequent of these being an isoform
of transketolase (TK). In addition, autoreactivity to selected
cytoskeletal proteins identified patients with secondary pro-
gressive MuS. Such newly identified antigenic targets, in
addition to having important pathogenetic implications, may
also serve as biomarkers of disease and could be useful
diagnostic and prognostic tools.
MATERIALS AND METHODS
Patients—Sera and CSF were obtained for diagnostic purposes
and after written informed consent from 38 subjects. Eighteen pa-
tients had clinically definite MuS with four primary progressive (PP),
eight relapsing-remitting (RR), and four secondary progressive (SP)
cases (17, 18); their clinical features are summarized in Table I. All
MuS patients had CSF oligoclonal bands, were relapse-free, and had
not received immunomodulating or immunosuppressive treatment
in the previous 6 months. Control sera and CSF were obtained from
20 subjects affected with meningoencephalitis (4), myelitis (4),
amyotrophic lateral sclerosis (3), neuropathy (3), and ischemic
stroke (2). Four additional subjects underwent lumbar puncture to
confirm meningitis but had spontaneous recovery and normal CSF
biological parameters.
CNS Samples—Normal human white matter samples (Brodmann
areas 4 and 6) for proteomics analysis were dissected out at autopsy
from two healthy subjects with no history of neurological disease (one
37-year-old woman and one 56-year-old man; postmortem interval,
24 h), and the samples were frozen and stored at 80 °C. Autoptic
CNS tissue from seven subjects (mean age, 51 years) with a clinical
diagnosis of chronic progressive MuS was studied for immunohisto-
chemical analysis. In total, 15 blocks containing lesions and normal
appearing white matter were examined. Histopathologically three
cases displayed a predominance of chronic active lesions, whereas in
the remaining four cases the majority of lesions were chronic silent.
2D PAGE and Immunoblotting—White matter samples were ho-
mogenized in lysis buffer (7 M urea, 2 M thiourea, 0.4% CHAPS,
0.1% DTT, 0.5% Triton X-100) and subjected to high resolution 2D
electrophoresis as reported previously (19). Isoelectrofocusing was
carried out on non-linear immobilized pH gradients (pH 3–10; 18-
cm-long IPG strips; GE Healthcare), and second dimension sepa-
ration was carried out on 9–16% SDS-polyacrylamide gradient
gels. The reference gel was stained with ammoniacal silver staining.
For the 2D immunoblotting (20, 21), gels were blotted onto 0.2-m
nitrocellulose membranes that were subsequently blocked with
10% BSA and 0.1% Tween in TBS for 2 h and incubated with sera
(diluted 1:10,000) or CSF (1:1,000) overnight. After washing, mem-
branes were incubated with anti-human IgG horseradish peroxi-
TABLE I
Demographic and clinical features of MuS and control patients
M, male; F, female.
Number 20 18 4 4 10
Agee 47.6±13.8 (22-71) 39.9±8.2 (29-59) 49.6±6.4 (44-59) 42.8±5.3 (38-52) 34.9±6.4 (29-48) 
Sex ratio M/F 14/7 10/8 3/1 2/2 5/5
Disease 
duration (yr)f
N.D.g 6.2±5.4 (0.5-24) 5.6±2.9 (3-10) 11±8.2 (4-24) 4.5±3.2 (2-12) 
a MuS, multiple sclerosis.
b PP, primary progressive.
c SP, secondary progressive.
d RR, relapsing-remitting.
e All numbers are expressed as mean  S.D. (range).
f At the moment of lumbar puncture.
g Expanded disability status scale evaluated at the moment of lumbar puncture.
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dase (HRP)-conjugated (1:3,000). Alternatively membranes were
incubated with antibodies to the following proteins: collapsin re-
sponse mediator proteins (CRMP) 5 (1:1,000) and 1 (1:30,000),
radixin (1:1,000; Chemicon, Temecula, CA), -centractin (1:50,000),
NAD-dependent deacetylase sirtuin 2 (1:50,000; Abcam, Cam-
bridge, UK), CNPase (1:20,000), actin (1:25,000), -tubulin
(1:35,000), neurofascin (1:2,500; Abcam), MOG (1:1,000; Sigma),
MBP (1:50,000), glial fibrillary acidic protein (1:200,000; Dako, Mi-
lan, Italy), TK (1:1,000) (22), and TK 1 (1:400; kindly provided by J. F.
Coy, R-Biopharm AG, Darmstadt, Germany). After incubation with
the appropriate secondary HRP-conjugated Ig, the signal was de-
veloped with Advanced ECL (Amersham Biosciences). Immune pro-
files were analyzed when two independent assays had produced
identical patterns. The reference 2D gel and autoradiographs were
analyzed and matched with the Image Master 2D Platinum v6.0
software (Amersham Biosciences).
Immunoprecipitation—Specific recognition of TK and CNPase I by
MuS CSF and serum was confirmed by testing the autoreactivity to
immunoprecipitated TK and CNPase. For this purpose, 0.5 mg of
CNS homogenate in buffer with 50 mM Tris-HCl, 150 mM NaCl, 1%
Nonidet P-40, 0.1% SDS, 1 mM EDTA, 0.5% deoxycholic acid, pH
7.5, with protease inhibitors was incubated with anti-CNPase or -TK
antibodies overnight at 4 °C. Protein A-agarose (Roche Applied Sci-
ence) was then added for 3 h. After centrifugation, immunoprecipi-
tated material was washed in cold TBS and extracted with lysis buffer.
After addition of 2 Laemmli buffer, immunoprecipitated proteins
were subjected to electrophoretic separation, blotted, and incubated
with the respective antibodies. In parallel, immunoprecipitated
CNPase was tested with four selected MuS sera (two of which rec-
ognized CNPase I by 2D immunoblotting), whereas immunoprecipi-
tated TK was probed with four selected MuS CSF samples (two cases
with anti-TK IgG reactivity).
Immunohistochemistry—Immunoperoxidase and double immu-
nofluorescence was performed for the identification of the cellular
localization of TK as described previously (5, 23). Briefly consecu-
tive paraffin or frozen sections from normal human CNS and MuS
cases were quenched and incubated with anti-TK antiserum and
the following antibodies: CNPase, MBP, PLP (Chemicon), or NG2
(Sigma). Reactivity was revealed with the appropriate biotinylated
antibody, avidin-biotin-HRP complex (Vector Laboratories, Burl-
ingame, CA), and the reaction was visualized with 3,3-diaminoben-
zidine as chromogen. In negative controls, primary antibodies were
omitted. Selected sections were then counterstained with hema-
toxylin. To characterize the phenotype of glial cells expressing TK,
double immunofluorescence was performed with glial phenotypic
markers (14). For this purpose, TK was detected by anti-rabbit
biotinylated antibody and avidin-Texas Red complex (Vector Lab-
oratories), whereas the monoclonal antibodies to the glial markers
CNPase, PLP, HLA-DR (Dako), NG2, and glial fibrillary acidic pro-
tein were identified with FITC-conjugated anti-mouse Ig.
In-gel Digestion and Protein Identification by Mass Spectrometry—
Protein identification was carried out by peptide mass fingerprinting
as described previously (24, 25). Electrophoretic spots, obtained from
preparative 2D gels run with 1 mg of white matter homogenate, were
visualized by an MS-compatible silver staining procedure (26, 27),
manually excised, destained, and acetonitrile-dehydrated. They were
then rehydrated in trypsin solution, and in-gel protein digestion was
performed by overnight incubation at 37 °C. Each protein digest (0.75
l) was spotted onto the MALDI target and allowed to air dry. Then
0.75 l of matrix solution (saturated solution of -cyano-4-hydroxy-
cinnamic acid in 50% (v/v) ACN and 0.5% (v/v) TFA) was applied to
the dried sample and dried again. MS analysis was performed using
an Ettan MALDI-TOF Pro mass spectrometer (GE Healthcare) in re-
flectron mode with an accelerating voltage of 20 kV. Mass spectra
FIG. 1. Protein map of the normal
human white matter. Normal human
white matter was resolved by 2D PAGE,
and the gel was subjected to silver stain-
ing; 243 of the spots recognized by IgG
from MuS and controls were identified
by MS and/or immunoblotting with spe-
cific antibodies and numbered from the
low molecular masses and acidic pH to
the high molecular masses and basic
pH. The identity of each protein and its
frequency of recognition by MuS IgG are
indicated in Table II.
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TABLE II
Proteins of the normal human white matter identified
Periods in sequences represent cleavage sites. NSF, N-ethylmaleimide-sensitive factor; MAP, mitogen-activated protein kinase.
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were acquired automatically using the Ettan MALDI Evaluation soft-
ware (GE Healthcare). Spectra were internally calibrated using the
autoproteolysis peptides of trypsin (842.51 and 2211.10 Da). All the
resulting mass lists were automatically cleaned up from contaminant
masses, such as those from matrix and autodigestion of trypsin and
keratins. All the spectra with the corresponding monoisotopic mass
list are presented in supplemental Document 1. Mass fingerprinting
searching was carried out in Swiss-Prot/TrEMBL 48.9 and NCBInr
20071013 databases using MASCOT (Matrix Science Ltd., London,
UK) on line-available software. The taxonomy was limited to Homo
sapiens, a mass tolerance of 100 ppm was allowed, and the number
of accepted missed cleavage sites was set to 1. Alkylation of cysteine
by carbamidomethylation was assumed as fixed modification,
whereas oxidation of methionine was considered as a possible mod-
ification. The experimental mass values were monoisotopic. No re-
strictions on protein molecular weight and pI were applied. The cri-
teria used to accept identifications included the extent of sequence
coverage, number of matched peptides, and probabilistic score
sorted by the software as detailed in Table II. Tryptic digests that did
not produce MALDI-TOF unambiguous identifications were subse-
quently acidified with 2 l of a 1% trifluoroacetic acid solution and
then subjected to ESI-ion trap MS/MS peptide sequencing on a
nanospray/LCQ DECA ion trap mass spectrometer (Thermo Finnigan,
San Jose, CA). Using ZipTipTM pipette tips for sample preparation
(Millipore, Billerica, MA) previously equilibrated in 50% acetonitrile
solution and abundantly washed in 0.1% trifluoroacetic acid, acidified
samples were enriched. Tryptic peptide elution from the ZipTip matrix
was achieved with a 70% methanol and 0.5% formic acid solution,
and 3 l of such concentrated sample solutions were then loaded in
a distal coated fused silica Picotip emitter to be nanosprayed in the
mass spectrometer. The collision energy was set based on the mass
of the precursor ions, which are doubly charged, and spectra were
acquired using Excalibur software (Thermo). All the MS/MS spectra
are provided in supplemental document 2, and identified peptides are
provided in Table II. MS/MS database searching was performed by
TurboSEQUEST (Thermo) and Mascot MS/MS ion search software
(Matrix Science) in the Swiss-Prot/TrEMBL 48.9 or NCBInr 20071013
databases. The following criteria were applied: MS accuracy, 1.2
Da, MS/MS mass accuracy, 0.6 Da, peptide precursor charge, 2,
monoisotopic experimental mass values, trypsin digestion with one
allowed missed cleavage, fixed carbamidomethylation of cysteine,
and variable oxidation of methionine.
Statistical Analysis—To perform the analysis of IgG autoreactivity
using 2 or Fisher exact test, the data were expressed in binary mode
(0  absence and 1  presence of immune reactive spot in all the
subjects tested). This descriptive approach allowed us to select the
most relevant spots in the serum and in the CSF, which supported
qualitatively different immune recognition between control and MuS
patients. In a second stage, all the reactive spots present exclusively
in MuS patients and having a p value 0.05 in the previous statistical
tests were considered alone or grouped according to their cellular
localization (i.e. proteins known to be present in cytoskeletal/neuro-
nal, oligodendroglial, or both compartments). Comparison of the
number of spots between MuS and control groups (either in serum or
CSF) was performed by Wilcoxon rank-sum test. Comparison be-
tween the number of spots and disease duration was performed with
Spearman rank correlation. To evaluate whether MuS clinical sub-
groups had different IgG autoreactivity to functional groups of pro-
teins, the number of reactive spots for each group was calculated in
all MuS cases; successively the Kruskal-Wallis test was used to
evaluate such scores in each MuS clinical subgroup.
RESULTS
Bidimensional electrophoretic separation of human white
matter proteins showed about 1,500 spots after silver stain-
ing, 350 of which were recognized by IgG of at least one
patient; the frequency of recognition of each spot is re-
ported in supplemental Table 1. By MS and/or immunoblot-
ting, we identified 243 of these spots (69%), which corre-
sponded to 120 distinct proteins (Fig. 1 and Table II); as
already described for rodent CNS (28), several isoforms
were detectable for most of these proteins. Among the
spots identified, those recognized exclusively and with high
frequency by MuS IgG were almost all included (supplemen-
tal Table 1); thus, this methodological approach provided an
exhaustive scenario of white matter antigens recognized by
autoantibodies present in serum and CSF of all the patients
examined.
CSF IgG Autoreactivity—No difference in the number of
spots recognized by CSF IgG was observed between MuS
TABLE II—continued
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(mean  S.D., 60.9  15.4; median, 63) and control groups
(mean  S.D., 62.9  18.3; median, 66). The frequency of
recognition of each reactive spot is listed in supplemental
Table 1. Table III summarizes the protein isoforms recognized
with higher frequency by CSF IgG from MuS patients as
compared with controls. All MuS patients displayed CSF re-
activity to at least one of these molecules. Among these, of
particular interest were those recognized exclusively by MuS
patients. All but one MuS patient reacted with at least one
isoform of TK, CNPase I, radixin, CRMP2, tubulin 4, NAD-
dependent deacetylase sirtuin 2, or actin-interacting protein 1
(Table IV and supplemental Fig. 1). As shown in Figs. 2 and 3,
2D PAGE separation of white matter antigens showed that most
of these proteins exclusively recognized by MuS CSF existed in
multiple isoforms. In addition, 2D immunoblotting provided
clear evidence that only single isoforms were specifically rec-
ognized by MuS IgG; the others also reacted with control sera.
In this regard, Fig. 2 shows the paradigmatic examples of the
recognition of TK and CRMP5 by CSF and serum MuS IgG,
respectively. Transketolase is a protein of 67.8 kDa and pI
7.4–7.6, and themore acidic isoformwas recognized by 50% of
MuS CSF and by 22% of MuS sera but not by controls (Fig. 2,
A and B, and Table III). Noteworthy is that such autoreactivity
would have been missed by monodimensional immunoblotting
because of the unspecific signals to the more basic TK isoforms
(Fig. 2, A and B) as well as to other molecules with similar
weight, such as albumin or heat shock proteins (Fig. 2A, arrow-
heads), which were recognized bymost controls. Recognition of
TK by CSF was confirmed by testing IgG from MuS and control
CSF against immunoprecipitated TK; for this purpose, we se-
lected two cases with reactivity to the MuS-specific isoform of
TK and two control CSF samples without TK immunoreactivity
by 2D immunoblotting. Monodimensional immunoblotting
showed an immunoreactive band at the same molecular weight
of TK only with MuS CSF (Fig. 2C). Interestingly when the
molecules recognized by MuS CSF IgG were grouped accord-
ing to their cellular distribution within the CNS, all but one MuS
patient displayed IgG autoreactivity to antigens expressed on
oligodendrocytes, such as CNPase I (29), tubulin 4 (30), TK
(Ref. 31 and next paragraph), and CRMP2 (32, 33) (Table IV).
IgG autoreactivity to the MuS-specific neuronal/axonal proteins
radixin, sirtuin 2, and actin-interacting protein 1 (34–36) was
present in a lower proportion of MuS CSF samples. Interestingly
the number of cytoskeletal molecules recognized by CSF IgG
was significantly higher in SP MuS (median, 1.25) than in PP
TABLE III
IgG autoreactivity to statistically relevant white matter proteins in MuS
and control patients
a Cerebrospinal fluid.
bp  0.05 in comparison with control patients.
TABLE IV
IgG autoreactivity in MuS patients to MuS-specific white matter
proteins grouped according to their cellular localization
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(median, 0.25) or RR (median, 0) MuS cases (p  0.001), and
such difference was not related to different disease duration
among MuS clinical subgroups (data not shown).
Cellular Localization of TK in Normal Human White Matter
and MuS Lesions—Prompted by the selective and frequent
recognition of TK by MuS IgG, we assessed its distribution
in normal human white matter and MuS lesions by immu-
noperoxidase and double immunofluorescence with glial
phenotypic markers. Transketolase is an enzyme of the
pentose phosphate pathway (PPP), which has been de-
scribed in neurons and oligodendrocytes in the rat brain
(31). In normal human brain we found that TK was ex-
pressed on nearly all mature oligodendrocytes and scat-
tered NG2-positive precursors, diffusely on ependymal
cells, and on distinct subsets of neuronal populations (Fig.
4, A–E). In MuS sections, TK immunoreactivity was still
present on oligodendrocytes in normal appearing white
matter up to the edge of both active and silent lesions and
markedly decreased in the core of demyelinated lesions
(Fig. 4, F and G). The comparative analysis of the signals for
TK and myelin proteins at the lesion border showed that
immunoreactivity for TK was more extensive than myelin
staining (Fig. 4, F–H). Double staining with glial phenotypic
markers in this area demonstrated the expression of TK on
subsets of NG2-positive oligodendrocyte precursors, reac-
tive astrocytes, and monocyte/macrophages (data not
shown). No major difference in terms of TK expression was
observed upon neurons or ependymal cells in comparison
with normal CNS samples (data not shown).
Serum IgG Autoreactivity—The number of spots reactive for
serum IgG was higher in MuS patients (mean  S.D., 60.8 
18.0; median, 62.5) as compared with control cases (mean 
S.D., 47.3  22.6; median, 46; p  0.0065). Regarding the
reactivity to the white matter proteins identified, supplemental
Table 1 shows the frequency of recognition of each spot,
whereas Table III summarizes the molecules recognized with
FIG. 2. MuS-specific neural protein
isoforms are selectively recognized by
serum and CSF IgG fromMuS patients.
Two examples of the advantages of 2D
immunoblotting for the recognition of
MuS-specific protein isoforms are shown.
A, focusing on the neural proteins at
65–70 kDa in the silver-stained gel (black
rectangle), it is evident that TK isoforms
(arrow) have a mass similar to that of the
series corresponding to heat shock pro-
teins and albumin (arrowheads). B and C,
pictures of 2D immunoblotting (of the
same areas corresponding to the rectan-
gles in A) of two membranes probed with
MuS (upper panel) and control (lower
panel) CSF. Immunoreactivity for the
more acidic TK isoform (arrow) is exclu-
sively present inMuSCSF. In addition, the
signal of the MuS-specific TK isoform vis-
ible on 2D immunoblotting (B) is clearly
distinguishable from heat shock proteins
(arrowhead), whose reactivity is present in
most patients. D, specificity of TK recog-
nition by MuS CSF is confirmed by using
immunoprecipitated TK. TK immunoreac-
tivity is visible at 67 kDa with specific an-
tiserum (right lane) and MuS CSF (left
lane; selected among those with anti-TK
reactivity) but not with CSF from controls
without anti-TK autoantibodies (central
lane); in all cases, a band corresponding
to IgG (used for immunoprecipitation) is
visible at 50 kDa. E, MuS-specific reactiv-
ity to one CRMP5 isoform in MuS serum;
of the two CRMP5 isoforms identified in
the silver-stained gel (upper panel), only
the more acidic isoform is specifically rec-
ognized by MuS serum (central panel),
whereas the other reacts also with control
sera (lower panel).
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higher frequency by serum IgG from MuS patients as com-
pared with controls. Focusing on MuS-specific reactivity, we
found that isoforms of CNPase I, -centractin, CRMPs 5 and
1, syntaxin-binding protein 1, TK, and pyruvate kinase were
recognized exclusively by IgG fromMuS sera (Fig. 3 and Table
III). All but two MuS sera displayed IgG reactivity to at least
one of these proteins (Table IV). Similarly to that described for
CSF reactivity, single isoforms of these proteins were recog-
nized by serum IgG from MuS patients but not from control
IgG (see the example of CRMP5 in Fig. 2E). Among MuS-
specific molecules, the most frequently recognized from MuS
sera were one isoform of CNPase I and two of syntaxin-
binding protein 1 (Table III). Noteworthy is that 2D immuno-
blotting showed that different isoforms of CNPase I were
recognized by IgG from serum and CSF of MuS patients (Fig.
3). Specific autoreactivity to CNPase was confirmed by im-
munoprecipitation (data not shown). When MuS-specific mol-
ecules were clustered according to their cellular distribution,
72% of MuS sera displayed autoreactivity to at least one of
the neuronal proteins -centractin, CRMP1, syntaxin-binding
protein 1 (33, 37)- and pyruvate kinase, whereas about 60% of
MuS patients had IgG reactivity to antigens localized (exclu-
sively or not) on oligodendrocytes (Table IV). Serum IgG au-
toreactivity to any MuS-specific protein or group of proteins
did not discriminate among MuS clinical subgroups (data not
shown).
Comparative Analysis of IgG Reactivity in Serum and CSF—
The comparative analysis of IgG autoreactivity to white matter
antigens detectable in serum and CSF of MuS patients
showed overall that different MuS-specific proteins or protein
isoforms were recognized with high frequency in these two
compartments (supplemental Table 1), and the results are
summarized in Fig. 3. In fact, only in the case of TK, the 2D
immunoblotting showed that both serum and CSF IgG from
three MuS cases reacted with the same TK isoform. Instead
different isoforms of CNPase I were recognized with high
frequency by serum and CSF IgG in MuS (Fig. 3). As for the
MuS-specific neuronal/axonal proteins, no autoreactivity was
detected in the serum for those molecules recognized by CSF
IgG (i.e. radixin, sirtuin 2, and actin-interacting protein 1).
Thus, the overall autoreactivity to white matter antigens pres-
ent in serum and CSF from MuS patients was directed to
different proteins, a strong evidence for a compartmentalized
autoimmune response. On the contrary, the comparative
analysis in control patients showed a more general overlap
between the neural proteins recognized by serum and CSF
IgG with about 40–50% of spots reacting with IgG from both
compartments.
IgG Autoreactivity to Other MuS-relevant Proteins—As for
the IgG reactivity to other MuS-relevant proteins, we focused
our attention on neurofascin (10), MBP (11, 12), MOG (11, 12),
transaldolase (38), -enolase (39), triose-phosphate isomer-
ase, and glyceraldehyde-3-phosphate dehydrogenase (40).
The present proteomics approach showed in general that IgG
autoreactivity to these MuS-relevant molecules was present
both in MuS and control patients. In fact, anti-transaldolase
IgG was detected only in one MuS serum, whereas anti-MOG
antibodies were observed in 65–90% of samples either in
MuS and control cases (supplemental Figs. 1 and 2). Autore-
activity to MBP isoforms was present in 5–20% of all patients
both in serum and CSF. In this regard, it would have been
interesting to establish whether one or more of the MBP
isoforms identified in our map were citrullinated because this
post-translational modification has suggested novel mecha-
nisms in the pathogenesis of MuS (41). Unfortunately we were
not able to establish whether one or more of the MBP iso-
forms identified in our map were citrullinated because we
identified this protein only by immunoblotting with a specific
antiserum but not by mass spectrometry. The frequency of
autoreactivity to -enolase depended on the isoform consid-
FIG. 3. MuS-specific proteins of normal human white matter. This figure summarizes the neural antigens recognized exclusively by MuS
patients among the complex array of IgG autoreactivity. Each protein of interest is present in multiple isoforms, but MuS specificity is limited
to one or two isoforms. The comparative analysis of the MuS-specific spots recognized by CSF (identified by white squares) and serum (white
circles) IgG showed the importance of post-translational modifications of putative MuS autoantigens and the compartmentalization of the
immune response in the blood and CSF with minimal overlap between the two groups of autoreactive proteins. Sirtuin 2, NAD-dependent
deacetylase sirtuin 2; STXB1, syntaxin-binding protein 1; AIP1, actin-interacting protein 1; KPYM, pyruvate kinase.
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ered, the more basic isoforms being recognized by most MuS
and control patients (supplemental Figs. 1 and 2) and the
other isoforms being recognized by 0–30% (both in serum
and CSF). Similar findings were observed for triose-phos-
phate isomerase and glyceraldehyde-3-phosphate dehydro-
genase whose more acidic isoforms were recognized by most
MuS and control CSF and the others by 15–35% of cases
(supplemental Figs. 1 and 2). Although we focused on a lower
range of molecular masses, both series of neurofascin iso-
forms (155 and 186 kDa) were present in our homogenate and
were recognized by 30–50% of both MuS and control pa-
tients. We failed to detect PLP in our human white matter map
and were unable to assess any autoreactivity to this molecule.
DISCUSSION
In the present study, we evaluated the patterns of autoim-
mune recognition of human white matter antigens by the
comparative analysis of autoreactive IgG repertoires present
in serum and CSF from MuS and control patients. We used a
bidimensional immunoblotting assay to develop a global ap-
proach against a large panel of natural antigens. A total of 350
spots were recognized by patients’ IgG (either from serum or
CSF), and the identification of two-thirds of these spots pro-
vided an exhaustive scenario of the autoreactivity of serum
and CSF IgG. In comparison with previous studies, which
addressed this topic by monodimensional immunoblotting
(39, 42, 43), our bidimensional approach showed the exist-
ence of multiple molecules with similar molecular weights; as
a consequence, immunoreactivity of these proteins would
probably overlap, and the discrimination of the single reactiv-
ities could be challenging. In addition, bidimensional immu-
noblotting underscored the importance of post-translational
modifications of neural proteins; in fact, only single isoforms
of a given neural protein were specifically recognized by MuS
patients and thus would be considered as MuS putative au-
toantigens. These lines of evidence highlight the limitation of
the monodimensional approach to study antibody autoreac-
tivity to CNS antigens. Despite the use of a high performance
method, we are aware that the analysis of IgG autoreactivity
to white matter antigens by (mono- or bidimensional) immu-
noblotting remains restricted. In fact, the electrophoretic pro-
cedure limits the analysis of autoantibody response to non-
conformational epitopes and to proteins with sufficiently high
levels of expression. With the limitation in mind that autore-
activity to low abundance proteins may have been under-
evaluated, our immunomics approach for the detection of IgG
autoantibodies to neural antigens in MuS patients and the
identification of the putative MuS autoantigens provided sev-
eral innovative clues with pathogenic and diagnostic rele-
vance for this disease. Our study confirmed that serum and
CSF IgG from all patients recognized multiple antigenic spots
of normal CNS homogenate resulting in a complex array of
IgG autoreactivity to white matter protein isoforms so that
distinct patterns were observed in each patient investigated
(39). Within such heterogeneous autoreactivity, the compara-
tive analysis of IgG repertoires of control and MuS patients
revealed the presence of a number of protein isoforms rec-
ognized exclusively and with high frequency by MuS patients
either in serum and CSF. As for MuS-specific autoantigens
recognized by serum IgG, the majority of MuS patients
displayed autoreactivity to at least one protein isoform lo-
calized in the neuronal/cytoskeletal compartment. Among
oligodendroglial molecules, serum autoantibodies to an iso-
form of CNPase I were present in 44% of MuS patients.
Such autoreactivity has already been reported in MuS pa-
tients using a similar proteomics approach (13); at variance
with our results where anti-CNPase I IgG recognized only a
specific isoform, in that study IgM but not IgG was found to
react to all CNPase I isoforms. Such a difference is probably
related to different technical conditions (such as serum
dilution and sensitivity of detection). Nevertheless both
studies showed the presence of anti-CNPase I serum au-
toantibodies in MuS patients and highlight the relevance of
this protein as an MuS seric marker.
The comparative analysis of the white matter antigens rec-
ognized by serum and CSF IgG fromMuS and control patients
provided a clear evidence for a compartmentalized autoim-
mune response in the CSF in MuS but not in control cases.
Our study in fact showed that the targets of autoreactive
serum MuS IgG were substantially different from those rec-
ognized by CSF MuS IgG. These results, together with the
recent anatomical and functional evidence of autonomous
liquoral immune response (44), highlight the limit of studies
assessing the presence of anti-myelin antibodies in the serum
of MuS patients. In fact, at variance with serum autoreactivity,
FIG. 4. Cellular distribution of transketolase in normal human CNS and MuS lesions. Immunoperoxidase with anti-TK antiserum on
paraffin sections from normal human CNS at bulbar (A and B) and cerebral (D) levels showed positive signals on numerous cells in the white
matter and ependyma; subpopulations of neurons are negative for TK (A), whereas others are clearly immunostained (D). B, at higher
magnification, TK immunoreactivity in the white matter is evident on small, round cells morphologically resembling oligodendrocytes. C, the
signal is abolished when the primary antibody is omitted. E, double immunofluorescence with anti-CNPase monoclonal antibody (E1, green)
and anti-TK antiserum (E2, red; E3, merge image) clearly shows that the majority of mature oligodendrocytes express high levels of TK in their
cytoplasm. Shown are consecutive sections immunostained with MBP (F) and TK (G) showing the edge of chronic MuS lesion; TK
immunoreactivity is visible in MBP-positive areas on the left but extended also in the demyelinated area. Double immunofluorescence pictures
taken at the edge of chronic MuS lesions from frozen sections show the distribution of PLP-positive oligodendrocytes (green; H1) and TK (H2)
with TK-positive cells present in normally myelinated areas and extending also on non-myelinating cells at the lesion border (H3). Original
magnification is as follows: A, 150; B and C, 400; D, 275; E, 750; F and G, 325; H, 400.
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which was mostly directed to cytoskeletal proteins, the ma-
jority of MuS CSF had IgG autoantibodies to non-myelin
oligodendroglial antigens. Among these, 50% of MuS CSF
samples displayed IgG reactivity to a specific isoform of TK, a
novel finding that may provide important information for the
pathogenesis of MuS. In fact, a reduced activity (because of
thiamine deficiency) of this highly conserved enzyme of the
PPP has been causally associated with Wernicke-Korsakoff
syndrome in which demyelination, neurodegeneration, and
blood-brain barrier damage are prominent pathological fea-
tures (45). Interestingly among the thiamine-dependent en-
zymes, the demyelinating features observed in such syn-
drome have been ascribed to TK deficiency because of its role
in fatty acid biosynthesis (46). As described previously in
rodent CNS (31), we indeed found that TK was mainly ex-
pressed by oligodendrocytes in normal conditions; in addi-
tion, we found that TK was also present in oligodendrocytes in
normal appearing white matter around MuS plaques, whereas
at the lesion border TK was expressed by oligodendrocyte
precursors, reactive astrocytes, and monocyte/macrophages.
This finding is probably related to the fundamental role played
by the PPP in the biosynthesis of nucleic acids and lipids
during brain development and remyelination (45). Whereas
under normal conditions the glucose is minimally metabolized
through the PPP in the brain, at times of rapid myelination up
to 60% of the cerebral glucose is metabolized via the PPP
because of the high rate of lipid biosynthesis (47). In addition
to its support to oligodendroglial biology, TK and the PPPmay
also be relevant to MuS pathogenesis because of their anti-
oxidant role exerted either in oligodendrocytes or neurons
(48). Concomitantly to an oxidative stress due to autoim-
mune-mediated TK deficiency, our results indicate that the
autoimmune response may also contribute to axonal/neuronal
damage present in MuS (15, 16). In fact, IgG autoreactivity in
MuS CSF was directed to a restricted number of neuronal/
axonal molecules, and the presence of autoantibodies to spe-
cific isoforms of sirtuin 2, radixin, and actin-interacting protein
1 was preferentially found in SP MuS patients, who showed
prominent neurodegeneration and irreversible neurological
deficits. The small group investigated prevents any clear con-
clusion about the pathogenic role of such anti-cytoskeletal
IgG in axonal degeneration in SP MuS, and we cannot ex-
clude that anti-cytoskeletal antibodies may be a consequence
of the axonal damage. However, the preferential CSF antineu-
ronal autoreactivity in SP MuS patients and the lack of asso-
ciation between the number of neuronal antigens recognized
by CSF IgG and the disease duration of MuS patients speaks
in favor of a pathogenic role for these autoantibodies. For this
purpose, additional information from longitudinal studies on a
larger group of patients as well as investigations on early
stages of MuS are needed.
Taken together, our approach shows that, within a complex
array of CNS autoreactivity, MuS patients displayed serum
and CSF autoantibodies to a restricted number of antigens
localized in oligodendrocytes and neurons/cytoskeleton.
Rather than exploring the presence of IgG to single myelin
proteins, our results suggest that the simultaneous investiga-
tion of multiple antigens may provide a more complete diag-
nostic and prognostic picture in MuS patients. Exploring the
role of non-conventional, non-myelin antigens may add in the
near future new and relevant information on MuS pathogen-
esis, and among these, TK may emerge as a target of CSF
autoimmune response.
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